Charles River Laboratories International (CRL) Competitors

$186.10 -3.75 (-1.97%)

Closing price 03:59 PM Eastern

Extended Trading

$185.13 -0.97 (-0.52%)

As of 04:51 PM Eastern

CRL vs. ICLR, TECH, A, IQV, and RVTY

Should you buy Charles River Laboratories International stock or one of its competitors? MarketBeat compares Charles River Laboratories International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Charles River Laboratories International include Icon (ICLR), Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), and Revvity (RVTY). These companies are all part of the "medical" sector.

How does Charles River Laboratories International compare to Icon?

Charles River Laboratories International (NYSE:CRL) and Icon (NASDAQ:ICLR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Icon has a net margin of 5.98% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Icon	5.98%	9.50%	5.40%

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 95.6% of Icon shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Charles River Laboratories International has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Icon has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Charles River Laboratories International currently has a consensus price target of $208.50, suggesting a potential upside of 12.04%. Icon has a consensus price target of $156.44, suggesting a potential upside of 8.19%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Icon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Icon	2 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.33

Icon has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.23	-$144.34M	-$3.76	N/A
Icon	$8.25B	1.34	$229.34M	$6.16	23.47

In the previous week, Charles River Laboratories International had 4 more articles in the media than Icon. MarketBeat recorded 7 mentions for Charles River Laboratories International and 3 mentions for Icon. Charles River Laboratories International's average media sentiment score of 1.05 beat Icon's score of 0.31 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Charles River Laboratories International beats Icon on 10 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Bio-Techne?

Charles River Laboratories International (NYSE:CRL) and Bio-Techne (NASDAQ:TECH) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Bio-Techne has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.23	-$144.34M	-$3.76	N/A
Bio-Techne	$1.22B	6.74	$73.40M	$0.69	76.09

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Bio-Techne	9.05%	13.57%	10.66%

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Charles River Laboratories International currently has a consensus target price of $208.50, indicating a potential upside of 12.04%. Bio-Techne has a consensus target price of $65.17, indicating a potential upside of 24.13%. Given Bio-Techne's stronger consensus rating and higher probable upside, analysts clearly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Bio-Techne	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Charles River Laboratories International has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

In the previous week, Charles River Laboratories International had 1 more articles in the media than Bio-Techne. MarketBeat recorded 7 mentions for Charles River Laboratories International and 6 mentions for Bio-Techne. Charles River Laboratories International's average media sentiment score of 1.05 beat Bio-Techne's score of 0.35 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bio-Techne beats Charles River Laboratories International on 10 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	5.36	$1.30B	$4.98	26.48
Charles River Laboratories International	$4.02B	2.23	-$144.34M	-$3.76	N/A

In the previous week, Agilent Technologies had 10 more articles in the media than Charles River Laboratories International. MarketBeat recorded 17 mentions for Agilent Technologies and 7 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.05 beat Agilent Technologies' score of 0.69 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies currently has a consensus price target of $161.71, suggesting a potential upside of 22.63%. Charles River Laboratories International has a consensus price target of $208.50, suggesting a potential upside of 12.04%. Given Agilent Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.94
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

Agilent Technologies has a net margin of 19.55% compared to Charles River Laboratories International's net margin of -4.59%. Agilent Technologies' return on equity of 24.33% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Agilent Technologies has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Agilent Technologies beats Charles River Laboratories International on 13 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

IQVIA (NYSE:IQV) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

IQVIA currently has a consensus price target of $224.13, indicating a potential upside of 22.96%. Charles River Laboratories International has a consensus price target of $208.50, indicating a potential upside of 12.04%. Given IQVIA's stronger consensus rating and higher possible upside, equities research analysts clearly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

IQVIA has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

IQVIA has a net margin of 8.33% compared to Charles River Laboratories International's net margin of -4.59%. IQVIA's return on equity of 30.50% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Charles River Laboratories International	-4.59%	15.36%	6.61%

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	1.87	$1.36B	$8.07	22.59
Charles River Laboratories International	$4.02B	2.23	-$144.34M	-$3.76	N/A

In the previous week, IQVIA had 9 more articles in the media than Charles River Laboratories International. MarketBeat recorded 16 mentions for IQVIA and 7 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.05 beat IQVIA's score of 0.47 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	5 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IQVIA beats Charles River Laboratories International on 12 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Revvity (NYSE:RVTY) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Charles River Laboratories International had 4 more articles in the media than Revvity. MarketBeat recorded 7 mentions for Charles River Laboratories International and 3 mentions for Revvity. Charles River Laboratories International's average media sentiment score of 1.05 beat Revvity's score of 0.46 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity currently has a consensus target price of $107.73, suggesting a potential upside of 6.36%. Charles River Laboratories International has a consensus target price of $208.50, suggesting a potential upside of 12.04%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	3.96	$241.20M	$2.09	48.46
Charles River Laboratories International	$4.02B	2.23	-$144.34M	-$3.76	N/A

Revvity has a net margin of 8.26% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.26%	8.00%	4.83%
Charles River Laboratories International	-4.59%	15.36%	6.61%

86.7% of Revvity shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Summary

Charles River Laboratories International beats Revvity on 11 of the 16 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$8.96B	$8.87B	$6.43B	$22.82B
Dividend Yield	N/A	1.76%	2.67%	4.11%
P/E Ratio	-49.50	24.39	24.49	30.13
Price / Sales	2.23	18.41	500.49	21.00
Price / Cash	8.49	87.37	42.36	23.85
Price / Book	2.89	5.45	10.43	4.59
Net Income	-$144.34M	$179.69M	$3.56B	$1.07B
7 Day Performance	3.33%	0.42%	-1.38%	-0.60%
1 Month Performance	4.58%	5.98%	0.86%	-1.14%
1 Year Performance	23.21%	0.73%	19.43%	18.94%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	3.0688 of 5 stars	$186.10 -2.0%	$208.50 +12.0%	+28.8%	$8.96B	$4.02B	N/A	19,700	Positive News
ICLR Icon	3.6766 of 5 stars	$144.12 +4.8%	$156.44 +8.5%	+8.7%	$11.11B	$8.25B	23.40	41,900	Earnings Report
TECH Bio-Techne	3.7974 of 5 stars	$50.85 +2.2%	$65.92 +29.6%	+9.1%	$7.79B	$1.22B	73.70	3,100	Analyst Downgrade
A Agilent Technologies	4.933 of 5 stars	$138.01 +2.2%	$161.71 +17.2%	+15.9%	$38.14B	$6.95B	27.71	18,100
IQV IQVIA	4.2425 of 5 stars	$182.12 +0.8%	$224.13 +23.1%	+20.8%	$30.15B	$16.31B	22.57	93,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Is CRL or ICLR more profitable?

Do institutionals & insiders have more ownership in CRL or ICLR?

Which has more volatility & risk, CRL or ICLR?

Do analysts prefer CRL or ICLR?

Which has higher valuation & earnings, CRL or ICLR?

Does the media favor CRL or ICLR?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Which has preferable earnings & valuation, CRL or TECH?

Is CRL or TECH more profitable?

Do institutionals and insiders have more ownership in CRL or TECH?

Do analysts rate CRL or TECH?

Which has more volatility & risk, CRL or TECH?

Does the media prefer CRL or TECH?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Which has better earnings & valuation, A or CRL?

Does the media favor A or CRL?

Do analysts prefer A or CRL?

Is A or CRL more profitable?

Which has more risk & volatility, A or CRL?

Do insiders and institutionals have more ownership in A or CRL?

Summary

How does Charles River Laboratories International compare to IQVIA?

Do analysts prefer IQV or CRL?

Which has more risk and volatility, IQV or CRL?

Is IQV or CRL more profitable?

Do institutionals and insiders believe in IQV or CRL?

Which has higher valuation and earnings, IQV or CRL?

Does the media favor IQV or CRL?

Summary

How does Charles River Laboratories International compare to Revvity?

Does the media refer more to RVTY or CRL?

Do analysts prefer RVTY or CRL?

Which has preferable earnings & valuation, RVTY or CRL?

Is RVTY or CRL more profitable?

Do insiders & institutionals have more ownership in RVTY or CRL?

Which has more risk and volatility, RVTY or CRL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools